Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Excision BioTherapeutics
3624 Market St., #514
Philadelphia, PA 19104

Excision BioTherapeutics Inc. is a life science company focused on the development and commercialization of advanced gene editing therapeutics for the treatment and eradication of life-threatening disease caused by neurotropic viruses (viral infections). The company was founded in 2015 out of Temple University's Lewis Katz School of Medicine in Philadelphia, PA. Company founders include Kamel Khalili, Ph.D., Thomas Malcolm, Ph.D., Rob Simmons, and David Rowe. The team has already produced a considerable intellectual property portfolio covering the use of the CRISPR and other gene editing tools in relation to a targeted pipeline of indications, as well as innovative companion diagnostics.

Key Contact
Name
Thomas Malcolm
Title
CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
Valuation
09/06/17 $10,000,000 Seed Artis Ventures
undisclosed